MDACC Study No:2013-0672 ( NCT No: NCT02014558)
Title:A Phase 1/2 Open-Label, Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP2215 in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Principal Investigator:Jorge Cortes
Treatment Agent:ASP2215
Study Status:Open
Study Description:The goal of this clinical research study is to learn about the safety of
ASP2215 when given to patients with relapsed or refractory AML and the effects
of other drugs on ASP2215. Researchers also want to learn if ASP2215 can help
to control AML. This is the first study using ASP2215 in humans.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase I/Phase II
Treatment Agents:ASP2215
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Astellas Pharma Global Development, Inc.
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Jorge Cortes
For Clinical Trial Enrollment:713-794-5783
For General Questions about Clinical Trials:1-877-MDA-6789

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults